Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Inclusion Criteria: * Patients with relapsing remitting Multiple Sclerosis * Patients with Expanded Disability Status Scale (EDSS) score of 0-6.5. Exclusion Criteria: * Patients with MS other than relapsing remitting MS * Patients with a history of chronic disease of the immune system other than MS, which requires systemic immunosuppressive treatment, or a known immunodeficiency syndrome. * Patients who have been treated with: * systemic corticosteroids or immunoglobulins within 1 month prior to baseline; * immunosuppressive medications within 3 months prior to baseline; * monoclonal antibodies within 3 months prior to baseline; * cladribine, mitoxantrone or alemtuzumab at any time. * Uncontrolled diabetes mellitus at screening * Diagnosis of macular edema during Screening Phase * Patients with active systemic bacterial, viral or fungal infections, or known to have AIDS, Hepatitis B, Hepatitis C infection or to have positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody tests. * Patients who have received total lymphoid irradiation or bone marrow transplantation. * Patients with certain cardiovascular conditions and/or findings in the screening ECG * Patients with certain liver conditions * Pregnant confirmed by a positive pregnancy test t or nursing (lactating) women * Other protocol-defined inclusion/exclusion criteria may apply.